EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patientsSin categorÃaMay 28, 2025
AL amyloidosis phase III clinical trial of birtamimab fails to meet primary endpointAL amyloidosisMay 26, 2025
European Commission approves linvoseltamab for the treatment of relapsed and refractory myelomaAccess, MyelomaApril 29, 2025
Register now to join the webinar ‘How do different countries make decisions on reimbursing new medicines?’Access, MPEMarch 6, 2025
EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patientsAccess, Myeloma, NewsMarch 3, 2025
